PRGO - Perrigo Company plc

NYSE - NYSE Delayed Price. Currency in USD
46.34
-1.43 (-2.99%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close47.77
Open47.59
Bid0.00 x 800
Ask0.00 x 1200
Day's Range46.21 - 47.89
52 Week Range36.28 - 78.90
Volume1,007,879
Avg. Volume1,249,995
Market Cap6.305B
Beta (3Y Monthly)1.94
PE Ratio (TTM)72.52
EPS (TTM)0.64
Earnings DateNov 6, 2019 - Nov 11, 2019
Forward Dividend & Yield0.84 (1.76%)
Ex-Dividend Date2019-08-29
1y Target Est51.67
Trade prices are not sourced from all markets
  • We Wouldn't Be Too Quick To Buy Perrigo Company plc (NYSE:PRGO) Before It Goes Ex-Dividend
    Simply Wall St.

    We Wouldn't Be Too Quick To Buy Perrigo Company plc (NYSE:PRGO) Before It Goes Ex-Dividend

    Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Perrigo...

  • Perrigo To Present At Upcoming Investor Conferences
    PR Newswire

    Perrigo To Present At Upcoming Investor Conferences

    TASE: PRGO), today announced that CEO and President, Murray S. Kessler and CFO, Ray Silcock, will host one-on-one meetings at the Barclay's Global Consumer Staples Conference on September 5, 2019 in Boston. TASE: PRGO) is dedicated to making lives better by bringing "Quality, Affordable Self-care Products™" that consumers trust everywhere they are sold. The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit Perrigo online at http://www.perrigo.com. Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements.

  • Perrigo Announces Patent Litigation Settlement for the Generic Version of Nascobal® Nasal Spray
    PR Newswire

    Perrigo Announces Patent Litigation Settlement for the Generic Version of Nascobal® Nasal Spray

    Perrigo Executive Vice President and President Rx Pharmaceuticals Sharon Kochan stated, "This settlement is another example of our long-term commitment and investments in our extended topicals strategy. TASE: PRGO) is dedicated to making lives better by bringing "Quality, Affordable Self-care Products™" that consumers trust everywhere they are sold. The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit Perrigo online at http://www.perrigo.com. Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements.

  • Barrons.com

    The 6 Worst Health-Care Stocks So Far This Month

    For health care investors this August, things could have been worse. But the past few weeks have been downright disastrous for some stocks.

  • Does Perrigo (NYSE:PRGO) Have A Healthy Balance Sheet?
    Simply Wall St.

    Does Perrigo (NYSE:PRGO) Have A Healthy Balance Sheet?

    Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

  • Thomson Reuters StreetEvents

    Edited Transcript of PRGO earnings conference call or presentation 8-Aug-19 12:00pm GMT

    Q2 2019 Perrigo Company PLC Earnings Call

  • PetIQ, Inc. (PETQ) Q2 2019 Earnings Call Transcript
    Motley Fool

    PetIQ, Inc. (PETQ) Q2 2019 Earnings Call Transcript

    PETQ earnings call for the period ending June, 30, 2019.

  • PRGO vs. BIO: Which Stock Is the Better Value Option?
    Zacks

    PRGO vs. BIO: Which Stock Is the Better Value Option?

    PRGO vs. BIO: Which Stock Is the Better Value Option?

  • Perrigo (PRGO) Q2 2019 Earnings Call Transcript
    Motley Fool

    Perrigo (PRGO) Q2 2019 Earnings Call Transcript

    PRGO earnings call for the period ending June 30, 2019.

  • Perrigo (PRGO) Beats on Q2 Earnings and Sales, Stock Up
    Zacks

    Perrigo (PRGO) Beats on Q2 Earnings and Sales, Stock Up

    Perrigo (PRGO) reports encouraging second-quarter 2019 results. The Rx segment recovers on strong new product sales.

  • TheStreet.com

    Perrigo Beats Second-Quarter Estimates but Stock Tumbles

    Perrigo is falling despite beating Wall Street's second-quarter earnings and revenue expectations.

  • Perrigo (PRGO) Tops Q2 Earnings and Revenue Estimates
    Zacks

    Perrigo (PRGO) Tops Q2 Earnings and Revenue Estimates

    Perrigo (PRGO) delivered earnings and revenue surprises of 6.17% and 1.58%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Benzinga

    Perrigo Reports Q2 Earnings, Reaffirms Guidance

    Perrigo Co (NYSE: PRGO) reported second-quarter earnings of 86 cents per share, which beat the analyst consensus estimate of 79 cents by 8.86%. The company reported quarterly sales of $1.127 billion, which missed the analyst consensus estimate of $1.13 billion by 0.27%.

  • MarketWatch

    Perrigo's stock surges after profit and revenue decline less than expected, outlook affirmed

    Shares of Perrigo Co. surged 6.0% in premarket trading Thursday, after the over-the-counter health and wellness products company reported second-quarter profit and revenue that beat expectations, and affirmed its full-year outlook. Net income fell to $9 million, or 7 cents a share, from $36 million, or 26 cents a share, in the year-ago period. Excluding non-recurring items, adjusted EPS fell to 86 cents from $1.22, above the FactSet consensus of 79 cents. Sales declined 3.1% to $1.15 billion but topped the FactSet consensus of $1.13 billion, as consumer self-care America sales fell 2.5%, consumer self-care international sales declined 8.5% and prescription pharmaceuticals sales rose 3.4%. The company affirmed its 2019 adjusted EPS outlook of $3.75 to $4.05. The stock has run up 30.3% year to date through Wednesday, while the S&P 500 has gained 15.0%.

  • Perrigo Company plc Reports Second Quarter 2019 Financial Results, Reaffirms Outlook, Progresses Consumer Transformation
    PR Newswire

    Perrigo Company plc Reports Second Quarter 2019 Financial Results, Reaffirms Outlook, Progresses Consumer Transformation

    DUBLIN , Aug. 8, 2019 /PRNewswire/ -- GAAP ("reported") net sales were $1.15 billion , reflecting a 3% decline versus the prior year period. Non-GAAP ("adjusted") net sales increased ...

  • PR Newswire

    Perrigo Announces Resignation Of Jeffrey C. Smith From Its Board Of Directors

    TASE: PRGO), a leading provider of "Quality Affordable Self-Care Products™", today announced that Jeffrey C. Smith, Managing Member, Chief Executive Officer, and Chief Investment Officer of Starboard Value LP, who has been a director since 2017, has resigned from Perrigo's Board of Directors effective August 7, 2019. "It is with mixed emotions that I leave the Board of Directors of Perrigo. "We are fortunate to have recruited a world-class leader in Murray Kessler who has quickly assembled an outstanding management team and repositioned Perrigo as a leading self-care company with numerous opportunities for growth and improved efficiency.

  • Benzinga

    Q2 Earnings Preview For Perrigo

    Perrigo Co (NYSE: PRGO ) releases its next round of earnings this Thursday, August 8. Get the latest predictions in Benzinga's essential guide to the company's Q2 earnings report. Earnings and Revenue ...

  • What's in the Cards for Perrigo (PRGO) This Earnings Season?
    Zacks

    What's in the Cards for Perrigo (PRGO) This Earnings Season?

    Perrigo (PRGO) is focused on Consumer Self Care Americas segment. It remains to be seen if this benefits the company's results in the soon-to-be reported quarter.

  • Analysts Estimate Perrigo (PRGO) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate Perrigo (PRGO) to Report a Decline in Earnings: What to Look Out for

    Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Perrigo Announces Quarterly Dividend
    PR Newswire

    Perrigo Announces Quarterly Dividend

    TASE: PRGO) is dedicated to making lives better by bringing "Quality, Affordable Self-care Products™" that consumers trust everywhere they are sold. The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit Perrigo online at (http://www.perrigo.com). Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements.

  • Perrigo Announces Second Quarter Calendar Year 2019 Earnings Date
    PR Newswire

    Perrigo Announces Second Quarter Calendar Year 2019 Earnings Date

    TASE: PRGO), today announced that it will release its second quarter calendar year 2019 financial results on Thursday, August 8, 2019. The Company will host a conference call beginning at 8 a.m. (EDT).

  • PRGO or SRDX: Which Is the Better Value Stock Right Now?
    Zacks

    PRGO or SRDX: Which Is the Better Value Stock Right Now?

    PRGO vs. SRDX: Which Stock Is the Better Value Option?

  • Is There An Opportunity With Perrigo Company plc's (NYSE:PRGO) 45% Undervaluation?
    Simply Wall St.

    Is There An Opportunity With Perrigo Company plc's (NYSE:PRGO) 45% Undervaluation?

    Today we will run through one way of estimating the intrinsic value of Perrigo Company plc (NYSE:PRGO) by taking the...

  • S&P 500 index tops 3,000 for first time — here’s how the stock market got here and what it means
    MarketWatch

    S&P 500 index tops 3,000 for first time — here’s how the stock market got here and what it means

    Five years in the making. That is essentially the time it has taken for the S&P 500 to hit a milestone mark at 3,000 for the first time in its history. The stock gauge first closed at 2,000 on Aug. 26, 2014, according to Dow Jones Market Data.

  • Markit

    See what the IHS Markit Score report has to say about Perrigo Company PLC.

    Perrigo Company PLC NYSE:PRGOView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is moderate and increasing * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for PRGO with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on June 24. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $2.32 billion over the last one-month into ETFs that hold PRGO are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.